-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – prexigebersen-A in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - prexigebersen-A in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Prexigebersen-A in Squamous Cell Carcinoma Drug Details: Prexigebersen-A is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – prexigebersen-A in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - prexigebersen-A in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Prexigebersen-A in Epithelial Ovarian Cancer Drug Details: Prexigebersen-A is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – prexigebersen-A in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - prexigebersen-A in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Prexigebersen-A in Endometrial Cancer Drug Details: Prexigebersen-A is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-8423 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-8423 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPL-8423 in Cystic Fibrosis Drug Details:SPL84-23-1 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – prexigebersen-A in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - prexigebersen-A in Uterine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Prexigebersen-A in Uterine Cancer Drug Details: Prexigebersen-A is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fesomersen Sodium in Thrombosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fesomersen Sodium in Thrombosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fesomersen Sodium in Thrombosis Drug Details:Fesomersen sodium (IONIS-FXILRX) is under development for the...
-
Company Profile
Antisense Therapeutics Ltd – Company Profile
Percheron Therapeutics Ltd (Percheron Therapeutics) formerly Antisense Therapeutics Ltd, is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of second-generation antisense pharmaceuticals. The company focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Percheron Therapeutics’ development pipeline comprises ATL1103 for a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being developed for the treatment...
Add to Basket -
Product Insights
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
HA-MRSA Infections Pipeline Drugs Market Report Overview Hospital-acquired methicillin-resistant staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warmth to the touch, fever, and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device, and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures. The HA-MRSA infections pipeline products market research report provides comprehensive information on the therapeutics under development for HA-MRSA infections, complete with analysis by...
-
Product Insights
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SMN Protein Pipeline Products Market Report Overview Survival of motor neurons or survival motor neurons (SMN) is a protein encoded by the SMN1 and SMN2 genes. The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs). They play an important role in the splicing of cellular pre-mRNAs. They ensure the correct splicing of U12 intron-containing genes that is important for normal motor and proprioceptive neuron development. They are required for resolving RNA-DNA hybrids created by...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...